Mon­tre­al AI start­up with a tout­ed ad­vi­sor li­cens­es its 'few-shot' plat­form to Re­pare for syn­thet­ic lethal­i­ty mol­e­cules

The rise of AI in drug dis­cov­ery has pre­sent­ed a buf­fet of tasty op­tions for drug­mak­ers to iden­ti­fy bet­ter mol­e­cules for hard-to-hit tar­gets. That promise is mixed, to say the least, but star­tups like Mon­tre­al’s Va­lence Dis­cov­ery think they’ve cracked the code — and at least one small biotech is con­vinced.

Va­lence, a re­cent­ly un­cloaked AI start­up spe­cial­iz­ing in deep learn­ing in drug dis­cov­ery, has li­censed its tech to Cana­da’s Re­pare Ther­a­peu­tics to iden­ti­fy ef­fec­tive syn­thet­ic lethal­i­ty mol­e­cules, the com­pa­nies said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.